In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 271 to 280 of 303

TitleTypeExpected publication date
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC
Tirzepatide for managing overweight and obesity [ID6179]Technology appraisal guidance
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]Technology appraisal guidanceTBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]Technology appraisal guidanceTBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Technology appraisal guidanceTBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]Technology appraisal guidanceTBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Technology appraisal guidance
Treatments for non-small-cell lung cancer [ID6234]Technology appraisal guidanceTBC
Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891Technology appraisal guidanceTBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All